- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00818350
Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer
Phase II Study of Sunitinib in Metastatic and Pretreated Urothelial Cancer
Gemcitabine and cisplatin represent the standard first-line chemotherapy in metastatic bladder carcinoma. This regimen has replaced in most centers the MVAC combination showing a similar efficacy but less toxicity.
Almost all responding patients relapse within the first year, with a median survival of 12 months. Prognosis is very poor in patients who display progressive disease after receiving combination cisplatin-based chemotherapy.
No standard has yet been established for second-line treatment and well designed trials of second-line chemotherapy for metastatic transitional carcinoma of the urothelium should be given high priority.
Several drugs have been used in second line for metastatic disease with poor results.
The investigators have planned a Phase II study, open-label, single arm design to evaluate the activity and safety of sunitinib in metastatic urothelial carcinoma, pretreated with standard regimen (cisplatin-gemcitabine).
No previous studies have been published with sunitinib in metastatic bladder cancer.
Study Overview
Detailed Description
OBJECTIVES
- PRIMARY To determine the antitumor efficacy ( response rate) of sunitinib
- SECONDARY To determine: safety, duration of response, Quality of life (QoL), progression free survival (PFS) and overall survival (OS).
PLAN OF TREATMENT Patients received sunitinib at a starting dose of 50 mg per day in repeated 6-week cycles for 4 consecutive weeks followed by 2 weeks off treatment.
Sunitinib was self-administered orally once daily without regard to meals. Dose reduction for toxicity was allowed to 37.5 until 25 mg/day depending on the type and severity of toxicity encountered.
Sunitinib treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent.
EVALUATION
Baseline evaluations included:
- medical history
- physical examination;
- tumor assessment (total body TC and bone scan )
- assessment of ECOG PS
- QoL assessment
- Assessment of left ventricular ejection fraction by echocardiography
- ECG
- Laboratory measurements. Assessment of efficacy and safety
- Evaluation according RECIST criteria every 2 cycles (12 weeks) with TC
- Safety according NCI version 3 every cycle
- QoL every cycle EORTC-QOL-C30.• RESOURCE UTILIZATION ASSESSMENTS
EORTC QLQ-C30 questionnaire, developed by the EORTC for the measurement of quality of life in cancer patients in clinical trials.
For the analysis, the raw scores of the questionnaire are transformed into a 100-point scale. For the functional scales, the computed scores range from 0 to 100, with the higher scores representing a higher level of functioning. For the item scales relative to physical symptoms and financial impact, higher scores represent a higher level of symptoms or problems .
STATISTICAL METHODS
Benefit anticipated (%): >30% of response rate. Test size: 5%. Power 80%. Sample size: 25 patients.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- cytological confirmation of UROTHELIAL carcinoma
- Failure of Cisplatin-gemcitabine regimen as first-line
- Presence of measurable metastases
- Performance status 0-1 ECOG
- Age of 18 years or older
- Written informed consent
- Adequate organ function ( based on tests of hematologic, hepatic, renal and cardiac function).
Exclusion Criteria:
- administration of a previous biological therapy ( sorafenib , bevacizumab or mTor Inhibitor)
- brain metastases
- significant cardiac events within the 6 months prior to study drug administration.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SUNITINIB
|
50 MG ORAL, DAYS 1-28 FOLLOWED BY 2 WEEKS RESTING
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the antitumor efficacy ( response rate) of sunitinib
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
QOL
Time Frame: 6 WEEKS
|
6 WEEKS
|
TOXICITY ACCORDING NCI VERSION 3 CRITERIA
Time Frame: EVERY WEEK
|
EVERY WEEK
|
Collaborators and Investigators
Investigators
- Principal Investigator: DI LORENZO GIUSEPPE, PHD, Campania Younger Oncologists Association
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Urinary Bladder Diseases
- Urinary Bladder Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Sunitinib
Other Study ID Numbers
- AGOC O1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Bladder Neoplasms
-
Peking University First HospitalRecruitingUrinary Bladder Cancer | Bladder Cancer | Bladder Neoplasms | Bladder Tumors | Neoplasms, BladderChina
-
GlaxoSmithKlineCompletedNeoplasms, Urinary BladderBelgium
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Bristol-Myers SquibbRecruitingUrinary Bladder Cancer | Invasive Bladder CancerNetherlands
-
Memorial Sloan Kettering Cancer CenterPfizerCompletedBladder Cancer | Urinary BladderUnited States
-
Mansoura UniversityCompletedBladder Cancer | Bladder Disease | Bladder Neoplasm | Micro-RNAEgypt
-
Medical University of ViennaUniversity of Turin, ItalyRecruitingT1 Urinary Bladder CancerAustria
-
Zhujiang HospitalRecruiting
-
Chinese University of Hong KongUnknownUrinary Bladder TumorHong Kong
-
Ziv HospitalAzrieli Faculty of medicine, Bar Ilan University, Safed, ILNot yet recruitingBladder Neoplasm
-
Ziv HospitalNot yet recruitingBladder Neoplasm
Clinical Trials on SUNITINIB
-
AGO Study GroupPhilipps University Marburg Medical Center; HSK Reasearch GmbH WiesbadenCompletedPlatinum Refractory Epithelial Ovarian Cancer | Primary Cancer of the Peritoneum | Cancer of the Fallopian TubeGermany
-
Mothaffar RimawiTerminated
-
Cogent Biosciences, Inc.RecruitingMetastatic Cancer | Advanced Gastrointestinal Stromal TumorsUnited States, Korea, Republic of, Spain, United Kingdom, Australia, France, Italy, Netherlands, Taiwan, Germany, Denmark, Hong Kong, Canada, Sweden, Norway, Mexico, Czechia, Argentina, Hungary, Brazil, Chile, Poland
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedKidney CancerUnited States
-
PfizerCompletedBreast NeoplasmsUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
PfizerCompletedGastrointestinal Stromal TumorsUnited States, Czechia, France
-
Asan Medical CenterCompletedMetastatic Renal Cell CarcinomaKorea, Republic of
-
PfizerCompletedGastrointestinal Stromal TumorsKorea, Republic of
-
California Pacific Medical Center Research InstitutePfizer; University of California, San FranciscoCompleted